Substance / Medication

Ketotifen fumarate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Atopic conjunctivitis

Allergic conjunctivitis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.

Avunduk Avni Murat, Tekelioglu Yavuz, Turk Adem et al. · Clin Ther · 2005

PMID: 16291412Trial

[Ketotifen fumarate (Zaditen) eye drops in the treatment of seasonal allergic conjunctivitis].

Haicl P, Cerná H · Cesk Slov Oftalmol · 2004

PMID: 15566225Trial

Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.

Abelson Mark B, Ferzola Nancy J, McWhirter Cecilia L et al. · Pediatr Allergy Immunol · 2004

PMID: 15610370Trial

Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.

Crampton H Jerome · Clin Ther · 2003

PMID: 12946545Trial

Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model.

Abelson Mark B, Chapin Matthew J, Kapik Barry M et al. · Arch Ophthalmol · 2003

PMID: 12742839Trial

A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.

Greiner Jack V, Minno George · Clin Ther · 2003

PMID: 12946546Trial

Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis.

Greiner Jack V, Mundorf Thomas, Dubiner Harvey et al. · Am J Ophthalmol · 2003

PMID: 14644221Trial

A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model.

Crampton H Jerome · Clin Ther · 2002

PMID: 12501875Trial

Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.

D'Arienzo Peter A, Leonardi Andrea, Bensch George · Clin Ther · 2002

PMID: 11952024Trial

A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.

Artal M N, Luna J D, Discepola M · Acta Ophthalmol Scand Suppl · 2000

PMID: 11057355Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ketotifen fumarate (substance)
SNOMED CT: 116098000
UMLS CUI: C0043443

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.